Tarsus Pharmaceuticals (TARS) PT Raised to $50 at Barclays
Tweet
Share
E-mailGet Alerts TARS Hot Sheet
Price: $70.02 --0%
Rating Summary:
10 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 9 | New: 8
Rating Summary:
10 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 9 | New: 8
Join SI Premium – FREE
Barclays analyst Balaji Prasad raised the price target on Tarsus Pharmaceuticals (NASDAQ: TARS) to $50.00 (from $40.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Tarsus Pharmaceuticals (TARS) PT Raised to $100 at Oppenheimer
- Andersen Group (ANDG) PT Raised to $54 at Morgan Stanley
- Neurocrine Bio. (NBIX) PT Lowered to $182 at Morgan Stanley
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
